Phio Pharmaceuticals (NASDAQ:PHIO) Issues Earnings Results, Beats Expectations By $0.11 EPS

Phio Pharmaceuticals (NASDAQ:PHIOGet Rating) posted its quarterly earnings data on Friday. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.11, MarketWatch Earnings reports.

Phio Pharmaceuticals stock opened at $0.71 on Friday. The stock has a 50-day moving average price of $0.98 and a 200 day moving average price of $1.08. Phio Pharmaceuticals has a 52 week low of $0.62 and a 52 week high of $2.47.

A number of large investors have recently modified their holdings of PHIO. Two Sigma Advisers LP increased its stake in shares of Phio Pharmaceuticals by 165.8% during the 3rd quarter. Two Sigma Advisers LP now owns 153,100 shares of the company’s stock valued at $311,000 after acquiring an additional 95,500 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Phio Pharmaceuticals by 6.8% during the 1st quarter. Vanguard Group Inc. now owns 304,119 shares of the company’s stock valued at $269,000 after acquiring an additional 19,242 shares during the last quarter. Millennium Management LLC increased its stake in shares of Phio Pharmaceuticals by 1,122.7% during the 3rd quarter. Millennium Management LLC now owns 122,693 shares of the company’s stock valued at $248,000 after acquiring an additional 112,658 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Phio Pharmaceuticals by 22.5% during the 3rd quarter. Geode Capital Management LLC now owns 107,192 shares of the company’s stock valued at $216,000 after acquiring an additional 19,691 shares during the last quarter. Finally, Cetera Investment Advisers increased its stake in shares of Phio Pharmaceuticals by 125.0% during the 1st quarter. Cetera Investment Advisers now owns 90,000 shares of the company’s stock valued at $80,000 after acquiring an additional 50,000 shares during the last quarter. 13.15% of the stock is currently owned by hedge funds and other institutional investors.

Separately, Zacks Investment Research cut Phio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday.

Phio Pharmaceuticals Company Profile (Get Rating)

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT.

See Also

Earnings History for Phio Pharmaceuticals (NASDAQ:PHIO)

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.